Clinical Trials Logo

Breast Lobular Carcinoma In Situ clinical trials

View clinical trials related to Breast Lobular Carcinoma In Situ.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05755269 Recruiting - Breast Carcinoma Clinical Trials

Adding a Genetic Risk Evaluation to Standard Breast Cancer Risk Assessment for African American and Hispanic Women

Start date: March 14, 2023
Phase:
Study type: Observational

This study evaluates whether adding a polygenic risk score evaluation to standard breast cancer risk assessment tools helps African American and Hispanic women make more informed decisions about accepting additional breast cancer screening and prevention strategies. Traditional breast cancer risk assessments rely mostly on the presence of standard clinical risk factors including family history, reproductive history, and mammographic breast density. This information can be combined with validated risk estimation models to provide a measure of a patient's 10 year and lifetime risk for breast cancer. A polygenic risk score helps to estimate breast cancer risk in a more individualized way by evaluating a patient's genetics. Adding a polygenic risk score evaluation to traditional screening techniques may help minority women make more informed decisions about screening and prevention strategies for breast cancer.

NCT ID: NCT04570956 Recruiting - Clinical trials for Breast Lobular Carcinoma in Situ

Oral Tamoxifen vs. TamGel vs. Control in Women With Atypical Hyperplasia or Lobular Carcinoma In Situ

Start date: July 26, 2021
Phase: Phase 2
Study type: Interventional

The investigators plan to prospectively study breast tissue changes after a short course of Tamoxifen (Tam).

NCT ID: NCT03979508 Recruiting - Clinical trials for Anatomic Stage III Breast Cancer AJCC v8

Abemaciclib in Treating Patients With Surgically Resectable, Chemotherapy Resistant, Triple Negative Breast Cancer

Start date: January 10, 2020
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well abemaciclib works in treating patients with triple negative breast cancer that can be removed by surgery (resectable) and does not respond to treatment with chemotherapy alone, or in combination with pembrolizumab. Abemaciclib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.